Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Edgewise news feed on Stock Titan aggregates company announcements, press releases, and other coverage related to its clinical programs, corporate developments, and financial updates.
Investors and observers following EWTX news will see regular updates on the company’s lead product candidates. These include sevasemten, an orally administered first-in-class fast skeletal myosin inhibitor in late-stage trials for Becker and Duchenne muscular dystrophies; EDG-7500, a cardiac sarcomere modulator in Phase 2 development for hypertrophic cardiomyopathy; and EDG-15400, a cardiac sarcomere modulator in Phase 1 development for heart failure. News items often describe trial progress, such as enrollment status, interim results, and plans for pivotal studies, as well as interactions with regulators.
The Edgewise news stream also features corporate and governance updates, including board and executive appointments, inducement equity grants under Nasdaq Listing Rules, participation in major healthcare and investor conferences, and periodic financial results. These disclosures provide context on how the company is building its organization and funding its research and development activities.
By monitoring this page, readers can review historical and recent EWTX news related to muscular dystrophy and cardiovascular programs, clinical milestones, and corporate actions as reported by the company in its public communications.
Edgewise Therapeutics (Nasdaq: EWTX) reported Q4 and full-year 2025 results, highlighted by strong program progress and $530.1M cash at year-end. Key near-term catalysts include CIRRUS-HCM 12-week Part D data and EDG-15400 Phase 1 topline in H1 2026, and pivotal GRAND CANYON sevasemten data in Q4 2026.
R&D and G&A expenses rose in Q4, and net loss was $50.2M ($0.47/share). The company plans an NDA timeline for sevasemten in H1 2027, pending results.
Edgewise Therapeutics (Nasdaq: EWTX) announced that COO Behrad Derakhshan, Ph.D. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 3:00 pm ET. The presentation will be webcast live and available for limited replay via the company Events & Presentations page.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity grants made January 30, 2025 to seven new non‑executive employees totaling 198,250 stock options under its 2024 Inducement Equity Incentive Plan.
Options have an exercise price of $28.15 (equal to the closing price on the grant date) and vest 25% after one year then 1/48th monthly thereafter, subject to continued service, granted pursuant to Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) outlined 2026 priorities including pivotal trial milestones, late‑stage cardiology readouts, and regulatory planning. The company completed enrollment in the GRAND CANYON pivotal cohort for sevasemten and expects top‑line results in Becker muscular dystrophy in Q4 2026, with a planned U.S. NDA submission in H1 2027. For cardiology programs, Edgewise expects CIRRUS‑HCM 12‑week data for EDG‑7500 in H1 2026 and aims to initiate Phase 3 in obstructive and nonobstructive HCM in H2 2026. The company raised approximately $200 million net proceeds from an April 2025 follow‑on offering to fund these programs. Management presented these updates at J.P. Morgan on Jan 13, 2026.
Edgewise Therapeutics (Nasdaq: EWTX) announced that Kevin Koch, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 8:15 am PT (11:15 am ET). The presentation will be webcast live and available for replay for a limited time on the company's Events & Presentations page. Attendees are advised to connect several minutes early to ensure a timely connection.
Edgewise Therapeutics (Nasdaq: EWTX) announced inducement stock option grants on December 31, 2025 to four new non-executive employees totaling 119,250 shares under its 2024 Inducement Equity Incentive Plan. Each option has an exercise price of $24.82, equal to the closing price on the grant date.
Vesting: 25% of each award vests on the one-year employment anniversary, then 1/48th of the shares vest monthly thereafter, subject to continued service. Grants were issued as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) reported completion of CIRRUS-HCM Parts B and C and favorable interim safety from Part D for EDG-7500, a selective oral cardiac sarcomere modulator for obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). Parts B/C enrolled 43 participants across 25 mg, 50 mg and 100 mg cohorts with improvements in NT-proBNP, KCCQ, NYHA and LVOT gradient (oHCM). Part D has >40 participants enrolled; ~70% reached ≥100 mg and 20 participants (8 oHCM, 12 nHCM) completed 12 weeks as of the Dec 23, 2025 cutoff. No clinically meaningful LVEF declines or LVEF <50% were observed. >300 ambulatory monitors captured >2,600 patient-days with no AF/flutter detected during monitoring; one AF event was reported and deemed not related to drug. Full Part D readout expected 2Q 2026; Phase 3 start targeted 4Q 2026.
Edgewise Therapeutics (NASDAQ:EWTX) announced inducement equity grants on November 28, 2025 related to a new non-executive hire. The company granted a stock option to purchase 26,250 shares under its 2024 Inducement Equity Incentive Plan.
The option exercise price is $26.04 per share (equal to the closing price on the grant date). Vesting is 25% after one year and then 1/48th monthly thereafter, subject to continued service. Grants were made as inducements under Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (Nasdaq: EWTX) announced on November 20, 2025 the appointment of Christopher Martin to its Board of Directors.
Mr. Martin brings commercial leadership across marketing, sales, market access, trade and business development and has led multiple product launches. The company said his experience will support preparations for its first commercial launch in Becker muscular dystrophy and efforts to advance its cardiovascular asset to Phase 3. Mr. Martin previously served as Chief Commercial Officer at Verona Pharma, acquired by Merck for approximately $10 billion in October 2025, and held senior commercial roles at SK Life Science, Cempra, Salix Pharmaceuticals and others. He holds a B.S. in Financial Management from Clemson University.
Edgewise Therapeutics (Nasdaq: EWTX) announced on November 12, 2025 that it granted inducement equity awards in connection with the hire of Michael Nofi as Chief Financial Officer, effective the same day. On November 10, 2025 the company granted a stock option to purchase 262,500 shares and an inducement restricted stock unit award covering 43,750 shares under the 2024 Inducement Equity Incentive Plan.
The option’s exercise price is $18.17 per share (equal to the grant‑date closing price). Vesting: options—25% after one year then 1/48th monthly; RSUs—1/4 each year for four years. Awards were granted as inducements per Nasdaq Listing Rule 5635(c)(4).